Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hetero Set To Join Indian Humira Biosimilar Line-Up

Executive Summary

Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.

Advertisement

Related Content

New Year Debut Of Another Biosimilar Humira In India
New Year Debut Of Another Biosimilar Humira In India
FDA Slams Hetero For Oversized Tablets And Dirty Equipment
Boehringer Ingelheim Limbering Up With Humira Biosimilar
India To Streamline Tiered Trial Approval Process – Will It Lift Sponsor Outlook?
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Another Humira Biosimilar Debuts In India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel